ABSTRACT
The current millennium has been marked by the emergence of 3 epidemics of coronavirus infection: severe acute respiratory syndrome (SARS, SARS-CoV or atypical pneumonia), Middle East respiratory syndrome (MERS-CoV) and, over the past year, severe acute respiratory syndrome caused by the new coronavirus infection (SARS). CoV2, COVID-19). COVID-19 turned out to be the most common, far ahead of other epidemics in terms of the number of infected and mortality. The use of a vaccine will undoubtedly become the most important method of combating a new pandemic, but its creation is associated with certain difficulties, both in terms of lack of time and due to the high rate of spontaneous mutations inherent in all RNA viruses and coronavirus in particular. In this regard, the development of effective treatment regimens aimed at inhibiting the virus, suppressing the secondary effects of the cytokine storm and/or modulating the body's immune system, as well as blocking some specific links in the pathogenesis of COVID 19 (for example, hypercoagulation) is a priority area of modern medicine. The article describes clinical observations demonstrating an improvement in the clinical status of patients while using the drug Areplivir (favipiravir), which blocks viral replication and has proven its efficacy in controlled trials. © 2021 Nutritec. All rights reserved.